国际流行病学传染病学杂志
國際流行病學傳染病學雜誌
국제류행병학전염병학잡지
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY AND INFECTIOUS DISEASE
2014年
3期
164-167
,共4页
肝炎,乙型,慢性%HBeAg%程序性死亡受体1%疗效
肝炎,乙型,慢性%HBeAg%程序性死亡受體1%療效
간염,을형,만성%HBeAg%정서성사망수체1%료효
Hepatitis B,chronic%HBeAg%Programmed death 1%Therapeutic effect
目的 探讨慢性乙型肝炎(CHB)患者抗病毒治疗不同时期外周血表面程序性死亡受体1(PD-1)和配体(PD-L1)的表达与HBeAg、ALT的关系.方法 对54例HBeAg阳性CHB患者予以拉米夫定(100 mg/d)联合阿德福韦酯(10 mg/d)治疗并随访24周,于治疗前、治疗4周、12周和24周收集外周血;同时选取同期健康体检者27人,抽取外周血.流式细胞仪检测外周血CD4+T细胞上PD-1和PD-L1的表达水平,同时检测CHB患者的ALT和HBeAg水平.结果 CHB患者治疗前PD-1和PD-L1的表达水平分别为(0.96±0.29)％和(0.49±0.18)％,高于正常对照组的(0.37±0.11)％和(0.16±0.07)％,差异有统计学意义(t=7.89、6.57,P＜0.01).治疗24周,PD-1和PD-L1分别下降为(0.58±0.19)％和(0.31±0.12)％,与治疗前比较差异均有统计学意义(t=4.83、3.86,P＜0.01);HBeAg血清转换组PD-1和PD-L1的表达水平分别为(0.49±0.16)％和(0.26±0.14)％,均低于HBeAg转阴组和HBeAg持续阳性组,差异有统计学意义(t=2.41、2.59,t=2.16、2.37,P均＜0.05);ALT复常者组PD-1和PD-L1的表达水平分别为(0.56±0.16)％和(0.29±0.14)％,均低于未复常者的(0.62±0.19)％和(0.33±0.16)％,但两组间差异无统计学意义(t=1.14、1.07,P＞0.05).结论 CHB患者血清PD-1和PD-L1水平较正常人升高,抗病毒治疗能够显著下调CHB患者外周血CD4+T细胞的PD-1和PD-L1的表达,同时治疗后PD-1和PD-L1的表达水平与患者血清HBeAg和ALT水平基本匹配.PD-1和PD-L1可能是反映CHB患者抗病毒治疗后病情好转的一个指标.
目的 探討慢性乙型肝炎(CHB)患者抗病毒治療不同時期外週血錶麵程序性死亡受體1(PD-1)和配體(PD-L1)的錶達與HBeAg、ALT的關繫.方法 對54例HBeAg暘性CHB患者予以拉米伕定(100 mg/d)聯閤阿德福韋酯(10 mg/d)治療併隨訪24週,于治療前、治療4週、12週和24週收集外週血;同時選取同期健康體檢者27人,抽取外週血.流式細胞儀檢測外週血CD4+T細胞上PD-1和PD-L1的錶達水平,同時檢測CHB患者的ALT和HBeAg水平.結果 CHB患者治療前PD-1和PD-L1的錶達水平分彆為(0.96±0.29)％和(0.49±0.18)％,高于正常對照組的(0.37±0.11)％和(0.16±0.07)％,差異有統計學意義(t=7.89、6.57,P＜0.01).治療24週,PD-1和PD-L1分彆下降為(0.58±0.19)％和(0.31±0.12)％,與治療前比較差異均有統計學意義(t=4.83、3.86,P＜0.01);HBeAg血清轉換組PD-1和PD-L1的錶達水平分彆為(0.49±0.16)％和(0.26±0.14)％,均低于HBeAg轉陰組和HBeAg持續暘性組,差異有統計學意義(t=2.41、2.59,t=2.16、2.37,P均＜0.05);ALT複常者組PD-1和PD-L1的錶達水平分彆為(0.56±0.16)％和(0.29±0.14)％,均低于未複常者的(0.62±0.19)％和(0.33±0.16)％,但兩組間差異無統計學意義(t=1.14、1.07,P＞0.05).結論 CHB患者血清PD-1和PD-L1水平較正常人升高,抗病毒治療能夠顯著下調CHB患者外週血CD4+T細胞的PD-1和PD-L1的錶達,同時治療後PD-1和PD-L1的錶達水平與患者血清HBeAg和ALT水平基本匹配.PD-1和PD-L1可能是反映CHB患者抗病毒治療後病情好轉的一箇指標.
목적 탐토만성을형간염(CHB)환자항병독치료불동시기외주혈표면정서성사망수체1(PD-1)화배체(PD-L1)적표체여HBeAg、ALT적관계.방법 대54례HBeAg양성CHB환자여이랍미부정(100 mg/d)연합아덕복위지(10 mg/d)치료병수방24주,우치료전、치료4주、12주화24주수집외주혈;동시선취동기건강체검자27인,추취외주혈.류식세포의검측외주혈CD4+T세포상PD-1화PD-L1적표체수평,동시검측CHB환자적ALT화HBeAg수평.결과 CHB환자치료전PD-1화PD-L1적표체수평분별위(0.96±0.29)％화(0.49±0.18)％,고우정상대조조적(0.37±0.11)％화(0.16±0.07)％,차이유통계학의의(t=7.89、6.57,P＜0.01).치료24주,PD-1화PD-L1분별하강위(0.58±0.19)％화(0.31±0.12)％,여치료전비교차이균유통계학의의(t=4.83、3.86,P＜0.01);HBeAg혈청전환조PD-1화PD-L1적표체수평분별위(0.49±0.16)％화(0.26±0.14)％,균저우HBeAg전음조화HBeAg지속양성조,차이유통계학의의(t=2.41、2.59,t=2.16、2.37,P균＜0.05);ALT복상자조PD-1화PD-L1적표체수평분별위(0.56±0.16)％화(0.29±0.14)％,균저우미복상자적(0.62±0.19)％화(0.33±0.16)％,단량조간차이무통계학의의(t=1.14、1.07,P＞0.05).결론 CHB환자혈청PD-1화PD-L1수평교정상인승고,항병독치료능구현저하조CHB환자외주혈CD4+T세포적PD-1화PD-L1적표체,동시치료후PD-1화PD-L1적표체수평여환자혈청HBeAg화ALT수평기본필배.PD-1화PD-L1가능시반영CHB환자항병독치료후병정호전적일개지표.
Objective To explore the relation of serum programmed death 1 (PD-1) and its ligands (PDL1) to HBeAg and ALT levels in chronic hepatitis B (CHB) patients undergoing antiviral treatment.Methods Fifty-four HBeAg positive patients underwent antiviral treatment with lamivudine (100 mg/d) and adefovir (10 mg/d) and followed up for 24 weeks.The peripheral blood were collected at four time points:before treatment,4,12 and 24 weeks after treatment.Twenty-seven healthy subjects were selected as controls.Serum PD-1/PD-L1 expressions on CD4+ T cells were assessed by flow cytometry.HBeAg and ALT were detected.Results The expressions of PD-1 and PD-L1 on CD4+ T cells in CHB patients were (0.96±0.29)％ and (0.49±0.18)％ before treatment,significantly higher than those of controls (t=7.89,6.57,P＜ 0.01).At 24 weeks,the expressions of PD-1 and PD-L1 in patients decreased to (0.58±0.19)％ and (0.31±0.12)％,respectively,with a significant difference compared to those before treatment (t=4.83,3.86,P all＜0.01).The expressions of PD-1 and PD-L1 in patients with HBeAg seroconversion was (0.49±0.16)％ and (0.26±0.14)％,respectively,both of which were lower than those in patients with HBeAg-negative and HBeAg-positive (t=2.41,2.59; t=2.16,2.37,P all ＜0.05).The levels of PD-1 and PD-L1 in patients with norml ALT after treatment were (0.56±0.16)％ and (0.29±0.14)％,respectively,both of which were lower than those in patients with sustained abnorml ALT [(0.62±0.19)％ and (0.33± 0.16)％],but no significant difference was noted between them (t=1.14,1.07,P all＞0.05).Conclusions Serum PD-1/PD-L1 expression on T lymphocyte was higher in patients with CHB than that in healthy people.Antiviral treatment can down-regulate the levels of PD-1 and PD-L1.The decease of PD-1 and PD-L1 corresponds with the decease of HBeAg and ALT,which indicates that PD-1 and PD-L1 may be used as predictive index for favorable outcome after antiviral treatment.
